Results of an international randomized phase III study show that pembrolizumab (Keytruda) as second-line therapy for advanced urothelial carcinoma provided superior overall survival and a better safety profile compared with commonly used chemotherapy options.
Chemoradiotherapy is an effective alternative to cystectomy in the primary management of muscle-invasive bladder cancer, British researchers say.
New research suggests that post-surgery symptoms may last for at least 3 months in cystectomy patients and worsen over time in some cases, posing unique management challenges for urologists.
The purpose of this article is to discuss important principles of radical cystectomy, whether performed using the open, laparoscopic, or robotic approach.
Cancer patients taking certain immunotherapy drugs may be more susceptible to developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a recent study.
An investigatory bladder cancer agent was associated with a 12-month high-grade recurrence-free survival of 35% for patients with Ta/T1 disease, researchers reported.
Nivolumab (Opdivo) is the second in class of immune checkpoint inhibitors approved for advanced bladder cancer—treatments that are having “tremendous responses across a spectrum of cancers,” says Leonard G. Gomella, MD.
Urology-related FDA approvals from 2016 encompassed drugs and devices for prostate cancer, renal cell carcinoma, bladder cancer, stone disease, and more.
Other pipeline developments discussed include an implantable device for OAB treatment, a subcutaneous hypogonadism treatment, efficacy results for an HPV drug, and the status of a device-based BPH treatment.
Sanofi Pasteur recently announced that it is discontinuing its BCG products TheraCys and ImmuCyst, prompting fears of a shortage of BCG for bladder cancer patients. In this interview, Dr. Benjamin J. Davies, associate professor of urology at the University of Pittsburgh School of Medicine, discusses the implications of the announcement and what’s next for patients and clinicians.